BioNexus Gene Lab Corp has made a significant move by entering into a CogniAI Healthcare Licence and Strategic Collaboration Agreement with Ruanyun Edai Technology Inc. This agreement, effective from October 5, 2026, allows BioNexus to utilize RYET's advanced document-intelligence platform exclusively in Malaysia. The collaboration is expected to enhance BioNexus's capabilities in the medical laboratory services sector, positioning the company for potential growth in a competitive market.
BioNexus Gene Lab Corp, listed on the Nasdaq under the ticker BGLC, operates in the medical laboratory services industry, specifically focusing on providing innovative healthcare solutions. The company, incorporated in Wyoming, has been actively engaging in strategic partnerships to expand its technological capabilities and market reach. This recent agreement is part of its ongoing efforts to leverage advanced technologies in the healthcare sector.
According to the filing, BioNexus will issue 410,000 common shares to RYET as part of the agreement, which has a total license consideration of $3.5 million. Additionally, BioNexus will issue another 150,000 shares in exchange for 500,000 ordinary shares of RYET. The licensing agreement is set for an initial term of ten years, with options for two five-year renewals, contingent on meeting specific milestones.
This collaboration is expected to impact various stakeholders, including healthcare providers in Malaysia who may benefit from the advanced capabilities of the CogniAI platform. The agreement also includes provisions for a 10% royalty on defined technology receipts, which could provide ongoing revenue for RYET.
As for the next steps, the closing of the agreement and the associated share issuances are pending. They are subject to several conditions, including satisfactory due diligence and required corporate and regulatory approvals. If closing does not occur by March 31, 2027, the agreement may be terminated unless extended by mutual consent.